|
1) 竹内 理, 審良静男. Toll-like receptorの生体防御における役割とそのシグナル伝達機構. 日本細菌学雑誌. 2004; 59: 523-9
|
|
|
|
2) 竹田 潔. 自然免疫: その理解から免疫疾患解明へのアプローチ. 実験医学. 2005; 23: 1502-5
|
|
|
|
|
|
3) 山本雅裕, 審良静男. Toll-like receptorを介したシグナル伝達機構と遺伝子発現制御. 実験医学. 2005; 23: 1506-11
|
|
|
|
|
|
4) 植松 智, 審良静男. Toll-like receptorによる生体防御機構. 日本内科学会雑誌. 2005; 94: 169-361
|
|
|
|
|
|
5) Akira S, Takeda K. Toll-like receptor signaling. Nat Rev Immunol. 2004; 4: 499-511
|
|
|
|
|
|
6) Takeda K, Akira A. Toll-like receptors in innate immunity. Int Immunol. 2005; 17: 1-14
|
|
|
|
|
|
7) de Kleijn D, Pasterkamp G. Toll-like receptors in cardiovascular diseases. Cardiovasc Res. 2003; 60: 58-67
|
|
|
|
|
8) Frantz S, Kelly RA, Bourcier T. Role of TLR-2 in the activation of nuclear factor kB by oxidative stress in cardiac myocytes. J Biol Chem. 2001; 276: 5197-203
|
|
|
|
|
|
9) Shishido T, Nozaki N, Yamaguchi S, et al. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation. 2003; 108: 2905-10
|
|
|
|
|
|
10) Oyama Ji, Blais C, Liu X, et al. Reduced myocardial ischemia-reperfusion injury in Toll-like receptor 4-deficient mice. Circulation. 2004; 109: 784-9
|
|
|
|
|
|
11) Frantz S, Kobzik L, Kim YD, et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 1999; 104: 271-80
|
|
|
|
|
|
12) Satoh M, Nakamura M, Akatsu T, et al. Toll-like receptor 4 is expressed with enteroviral replication in myocardium from patients with dilated cardiomyopathy. Lab Invest. 2004; 84: 173-81
|
|
|
|
|
|
13) Methe H, Kim JO, Kofler S, et al. Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation. 2005; 111: 2654-61
|
|
|
|
|
|
14) Balistreri CR, Candore G, Colonna-Romano G, et al. Role of Toll-like receptor 4 in acute myocardial infarction and longevity. JAMA. 2004; 292: 2339-40
|
|
|
|
|
|
15) Kolel MJ, Carlquist JF, Muhlestein JB, et al. Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. Am Heart J. 2004; 148: 1034-40
|
|
|
|
|
|
16) Riad A, Jaeger S, Sobirey M, et al. Toll-like receptor-4 modulates survival by induction of left ventricular remodeling after myocardial infarction in mice. J Immunol. 2008; 180: 6954-61
|
|
|
|
|
|
17) Timmers L, Sluijter JPG, van Keulen JK, et al. Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res. 2008; 102: 257-64
|
|
|
|
|
|
18) Yang H, Wang H, Czura CJ, et al. The cytokine activity of HMGB1. J Leukoc Biol. 2005; 78: 1-8
|
|
|
|
|
|
19) Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999; 285: 248-51
|
|
|
|
|
|
20) Limana F, Germani A, Zacheo A, et al. Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac c-Kit＋ cell proliferation and differentiation. Circ Res. 2005; 97: e73-83
|
|
|
|
|
|
21) Chavakis E, Hain A, Vinci M, et al. High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circ Res. 2007; 100: 204-12
|
|
|
|
|
|
22) Mitola S, Belleri M, Urbinati C, et al. Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. J Immunol. 2006; 176: 12-5
|
|
|
|
|
|
23) Kitahara T, Takeishi Y, Harada M, et al. High-mobility group box 1 restores cardiac dysfunction after myocardial infarction in transgenic mice. Cardiovasc Res. 2008; 80: 40-6
|
|
|
|
|